IBI 308

Drug Profile

IBI 308

Alternative Names: Anti-PD-1-antibody-Cinda; IBI308

Latest Information Update: 06 Dec 2016

Price : $50

At a glance

  • Originator Innovent Biologics
  • Developer Cinda Biopharmaceutical; Eli Lilly; Innovent Biologics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Discontinued Non-Hodgkin's lymphoma

Most Recent Events

  • 19 Apr 2017 Innovent Biologics plans a phase II trial for Oesophageal squamous cell cancer (Metastatic disease, Late-stage disease, Second-line therapy or greater, Inoperable/unresectable) (NCT03116152)
  • 18 Apr 2017 Innovent Biologics plans the ORIENT-1 phase II trial for Hodgkin's disease (Refractory metastatic disease, Second-line therapy or greater) (NCT03114683)
  • 01 Oct 2016 Discontinued for Non-Hodgkin's lymphoma in China before October 2016 (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top